Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse MKT  >  Protalix Biotherapeutics Inc    PLX

PROTALIX BIOTHERAPEUTICS INC (PLX)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse Mkt
04/16/2018 04/17/2018 04/18/2018 04/19/2018 04/20/2018 Date
0.4511(c) 0.45(c) 0.45(c) 0.4408(c) 0.4258(c) Last
281 796 558 145 130 507 330 832 362 951 Volume
-4.02% -0.24% 0.00% -2.04% -3.40% Change
More quotes
Financials (USD)
Sales 2013 15,8 M
EBIT 2013 -19,9 M
Net income 2013 -19,0 M
Debt 2013 -
Yield 2013 -
Sales 2014 35,8 M
EBIT 2014 -12,9 M
Net income 2014 -4,70 M
Debt 2014 -
Yield 2014 -
P/E ratio 2013 -
P/E ratio 2014
Capi. / Sales2013 3,94x
Capi. / Sales2014 1,73x
Capitalization 62,0 M
More Financials
Company
Protalix Biotherapeutics, Inc. engages in the development and commercialization of recombinant therapeutic proteins based on ProCellEx plant cell based expression system.It offers Taliglucerase alfa injections under the brand name Elelyso, an enzyme replacement therapy for Gaucher disease.The... 
More about the company
Surperformance© ratings of Protalix Biotherapeutics I
Trading Rating : Investor Rating :
More Ratings
Latest news on PROTALIX BIOTHERAPEUTICS I
04/16PROTALIX BIOTHERAPEUTICS, INC. : Submission of Matters to a Vote of Security Hol..
AQ
03/27PROTALIX BIOTHERAPEUTICS : Reports 2017 Full Year Results and Provides Corporate..
AQ
03/22PROTALIX BIOTHERAPEUTICS : Announces Acceptance of Abstract on OPRX-106 as a Lec..
AQ
03/21PROTALIX BIOTHERAPEUTICS, INC. : Regulation FD Disclosure (form 8-K)
AQ
03/20PROTALIX BIOTHERAPEUTICS INC : Protalix BioTherapeutics, OPRX-106 Phase II Resul..
AC
03/19PROTALIX BIOTHERAPEUTICS : to Present at BioCentury's 25th Annual Future Leaders..
AQ
03/19Protalix BioTherapeutics Announces Acceptance of Abstract on OPRX-106 as a Le..
GL
03/16PROTALIX BIOTHERAPEUTICS : Announces Positive Results from Phase II Clinical Tri..
AQ
03/15PROTALIX BIOTHERAPEUTICS : to Present at BioCentury’s 25th Annual Future L..
AQ
03/14PROTALIX BIOTHERAPEUTICS : Announces Positive Results from Phase II Clinical Tri..
AQ
More news
Sector news : Biotechnology & Medical Research - NEC
04/19Novartis CEO feels heat on U.S. generics, Cosentyx drop
RE
04/17GE rides gene therapy wave with ready-made viral drug factories
RE
04/12GSK slims portfolio with sale of rare disease gene therapy drugs
RE
04/12UK gene therapy firm Orchard plans stock offer after GSK deal
RE
04/12TAKEDA SOUNDS OUT BANKS FOR LOANS AS : sources
RE
More sector news : Biotechnology & Medical Research - NEC
Chart PROTALIX BIOTHERAPEUTICS I
Duration : Period :
Protalix Biotherapeutics I Technical Analysis Chart | PLX | US74365A1016 | 4-Traders
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 6,50 $
Spread / Average Target 1 359%
EPS Revisions
Managers
NameTitle
Moshe Manor President, Chief Executive Officer & Director
Shlomo Yanai Chairman
Tzvi Palash Chief Operating Officer
Yossi Maimon CFO, Secretary, Treasurer & Vice President
Yoseph Shaaltiel Executive Vice President-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
PROTALIX BIOTHERAPEUTICS INC-35.60%62
CELLTRION, INC.--.--%31 467
IQVIA HOLDINGS INC-0.64%20 258
LONZA GROUP-6.95%18 703
INCYTE CORPORATION-27.09%14 493
NEKTAR THERAPEUTICS44.36%13 873